Portugal – Antineoplastic and immunomodulating agents – 2023/0491- RUXOLITINIB [20 MG CÁP/COMP]
Tender Description
RUXOLITINIB [20 MG CÁP/COMP]
Unlock Full Tender Insight
Complete details, deadlines, and AI-powered analysis are available inside the tend.ee platform. Create your free account to access.
It's free to get started. No credit card required.
